Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

m the Department of Chemistry, Bar-Ilan University; and Ada Rephaeli, Ph.D., Professor Abraham Weizman, MD, and Irit Gil-Ad, Ph.D. from the Sackler Faculty of Medicine, Tel Aviv University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx seeks to enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.

This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," "scheduled" and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Contact

BioLineRx Ltd.
Yuri Shoshan, +972-2-548-9100
VP Finance and Corporate Development
yuri@biolinerx.com
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:9/19/2014)... HILL, N.C. , Sept. 19, 2014 ... to Best Practices, LLC with three issues he wanted ... , The use of external personnel (especially for secondary ... headcount in the face of increased workload , ... and better knowledge management , How to implement ...
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Hydrochloride listing their product specification, capacity, Production ...
(Date:9/19/2014)... 2014 Kiromic, LLC, a Lubbock ... Hance , the former chancellor of Texas Tech University, to ... in July 2014, after raising $1.2 billion for the university. ... Hance , the most successful chancellor in the history of ... as an investor, but also as our new vice chairman ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:9/20/2014)... Dallas, TX (PRWEB) September 20, 2014 ... – Forecast and Market Analysis to 2023?. The ... past decade, as it has become saturated with ... (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting ... been facing increasing generic competition. However, the launch ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Earlier this week, ... customers may have had their credit card information pilfered by ... spawning a slew of headline articles like this one ... the only eye opening numbers. , “Most people tend ... almost like it’s a way to score a game,” says ...
(Date:9/20/2014)... Final Cut Pro X Plugin ... the Information theme for FCPX filmmakers. , “Fun, cool, and ... Information theme,” says Christina Austin, CEO of Pixel Film Studios. ... , Information features easy to use controls that give the ... Change the background color, color of each circle outline, the ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2
... in Higher Education (AGHE), the educational branch of ... its 35th Annual Meeting and Educational Leadership Conference ... Plaza Hotel-Riverwalk in San Antonio, TX. This conference ... aging to present their work and share ideas about ...
... without spending,a lot of cash? It,s true. In fact, you ... boosting your health, lowering your stress level and,cleaning out your ... Hilling has spent more than 15 years researching,and designing products ... With the ten thrifty tips, this host of "Skin Health ...
... RED BANK, New Jersey, BRUSSELS and MELBOURNE, January 30, ... over a century of expertise, the global leader in ... the web. The,new http://www.ansell.com website is now ... new Investor Centre. , The ...
... Studies Initiated in Other Oncology SettingsLONDON and COPENHAGEN, ... A/S (OMX: GEN) announced today the submission of ... Food and Drug Administration (FDA) for Arzerra(TM) ... leukemia (CLL) is resistant (refractory) to previous therapies. ...
... and LISLE, Ill., Jan. 30 SpineMark Corporation,a ... and,physicians to develop Spine Centers of Excellence, has ... high quality spinal care at,cost effective rates through ... Management solution, the Healthplace Surgery Benefit(TM). As ...
... Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... partnership with physicians and manager of Physhield Insurance ... the following letter to its shareholders:Dear Phyhealth Shareholder:We ... and a new administration in Washington. Healthcare ...
Cached Medicine News:Health News:Teaching about financial crisis among Gerontology Meeting's highlights 2Health News:Ten Thrifty Tips for Radiant Skin 2Health News:Ten Thrifty Tips for Radiant Skin 3Health News:Ansell Limited Launching a New Global Website 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 3Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 4Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 5Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 6Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 7Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 8Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4
Knife rasp for shoulder arthroscopy....
Loop handle knot pusher...
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: